US Patent Issued to In3Bio on March 25 for "Methods and compositions for inhibition of EGF/EGFR pathway in combination with tyrosine kinase inhibitors" (Belgian, Spanish Inventors)

ALEXANDRIA, Va., March 26 -- United States Patent no. 12,258,389, issued on March 25, was assigned to In3Bio Ltd. (Hamilton, Bermuda).

"Methods and compositions for inhibition of EGF/EGFR pathway in combination with tyrosine kinase inhibitors" was invented by Erik D'Hondt (Bazel, Belgium) and Miguel Angel Molina Vila (Badalona, Spain).

According to the abstract* released by the U.S. Patent & Trademark Office: "A method of treating patients suffering from cancers driven by deregulated Human Epidermal Growth Factor Receptor (HER1/Human EGFR) comprising administering to a patient in need of such treatment a flexible and active regimen for combining a tyrosine kinase inhibitor (TKI) and anti-EGF antibodies for inhibition of the pathway activa...